Global Personalized Cancer Medicine Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Personalized Cancer Medicine market size was valued at US$ 197960 million in 2024 and is forecast to a readjusted size of USD 439260 million by 2031 with a CAGR of 12.2% during review period.
Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patients cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patients tumor.
Immunotherapies: While not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patients immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumors molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patients cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.
In the global market, the core manufacturers of Precision Cancer Medicine (Personalised Cancer Medicine) are AbbVie, Johnson & Johnson, Novartis, and others. The top three players within this industry account for about 30% of the market share. North America, Europe, and Asia Pacific are the major manufacturing regions for this product, with North America accounting for over 50% of the global market share. The product can be classified on the basis of treatment into immunotherapy and targeted therapy drugs. The product is widely used in the treatment of lung, breast, prostate, blood and other cancers.
This report is a detailed and comprehensive analysis for global Personalized Cancer Medicine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Method and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Personalized Cancer Medicine market size and forecasts, in consumption value ($ Million), 2020-2031
Global Personalized Cancer Medicine market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Personalized Cancer Medicine market size and forecasts, by Method and by Application, in consumption value ($ Million), 2020-2031
Global Personalized Cancer Medicine market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Personalized Cancer Medicine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Personalized Cancer Medicine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Personalized Cancer Medicine market is split by Method and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Method and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Method
Cancer Immunotherapy
Targeted Therapy
Market segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
Market segment by players, this report covers
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Personalized Cancer Medicine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Personalized Cancer Medicine, with revenue, gross margin, and global market share of Personalized Cancer Medicine from 2020 to 2025.
Chapter 3, the Personalized Cancer Medicine competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Method and by Application, with consumption value and growth rate by Method, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Personalized Cancer Medicine market forecast, by regions, by Method and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Personalized Cancer Medicine.
Chapter 13, to describe Personalized Cancer Medicine research findings and conclusion.
Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patients cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patients tumor.
Immunotherapies: While not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patients immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumors molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patients cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.
In the global market, the core manufacturers of Precision Cancer Medicine (Personalised Cancer Medicine) are AbbVie, Johnson & Johnson, Novartis, and others. The top three players within this industry account for about 30% of the market share. North America, Europe, and Asia Pacific are the major manufacturing regions for this product, with North America accounting for over 50% of the global market share. The product can be classified on the basis of treatment into immunotherapy and targeted therapy drugs. The product is widely used in the treatment of lung, breast, prostate, blood and other cancers.
This report is a detailed and comprehensive analysis for global Personalized Cancer Medicine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Method and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Personalized Cancer Medicine market size and forecasts, in consumption value ($ Million), 2020-2031
Global Personalized Cancer Medicine market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Personalized Cancer Medicine market size and forecasts, by Method and by Application, in consumption value ($ Million), 2020-2031
Global Personalized Cancer Medicine market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Personalized Cancer Medicine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Personalized Cancer Medicine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Personalized Cancer Medicine market is split by Method and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Method and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Method
Cancer Immunotherapy
Targeted Therapy
Market segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
Market segment by players, this report covers
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Personalized Cancer Medicine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Personalized Cancer Medicine, with revenue, gross margin, and global market share of Personalized Cancer Medicine from 2020 to 2025.
Chapter 3, the Personalized Cancer Medicine competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Method and by Application, with consumption value and growth rate by Method, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Personalized Cancer Medicine market forecast, by regions, by Method and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Personalized Cancer Medicine.
Chapter 13, to describe Personalized Cancer Medicine research findings and conclusion.
Table of Contents
122 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Method
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
